Lynn Silver is an independent consultant to the pharmaceutical industry in antibacterial discovery and pre-clinical development, generally applying her experience in pharmaceutical and academic research to the problems and projects of antibacterial discovery.
She earned her BA at Brandeis University in Biology and her PhD at Tufts University in Molecular Biology and Microbiology. She did postdoctoral work in the Département de Biologie Moléculaire at the Université de Genève and the Laboratory of Biochemical Pharmacology at NIH.
Dr. Silver was employed at Merck Research Laboratories from 1982 to 2003 where she conducted research and supervised groups in discovery efforts for new antibacterials in both natural products (NPs) and chemical collections. Her expertise includes broad knowledge of antibacterial agents, screen design and execution, microbiological evaluation of hits and leads, and studies of mechanism of action and resistance. She participated in the discovery of the novel antibiotic platensimycin and the first published inhibitors of LpxC.
She was a member of several drug-development project teams including that of the carbapenem INVANZÒ. Throughout her career, she has authored significant research papers and reviews in the field of bacterial genetics, physiology, and biochemistry, as well as discovery and analysis of antibacterial agents.
She is a member of the Editorial Boards of Antimicrobial Agents and Chemotherapy and ACS Infectious Diseases, has been a member of many SABs and NIH study sections.
She has spoken at and chaired numerous meetings focused on antibacterial discovery. She was elected a Fellow of the American Academy of Microbiology in 2018.